The Phase 1 data strongly supports JADE101's best-in-class potential with Q12W dosing, a key competitive advantage. Monitor JUNIPER Phase 2 interim data expected in 2027 for UPCR-24 results and the planned Phase 3 start in 1H 2027. The stock likely re-rates on pipeline de-risking; watch for near-term volatility from analyst assessments of cross-trial comparisons vs sibeprenlimab/povetacicept.
Price Chart
Executive Summary
Jade Biosciences reported interim Phase 1 data for JADE101, an anti-APRIL antibody for IgAN. The data showed ~70% mean IgA reduction sustained at 12 weeks at the 700 mg dose, a favorable safety profile, and PK/PD modeling supports every-12-week subcutaneous maintenance dosing. This supports advancing to Phase 2 (JUNIPER, already started) and a planned registrational Phase 3 trial in 1H 2027. The positive clinical data de-risks the program and supports best-in-class positioning in a large $20B+ addressable market.
Key Facts
- Mean IgA reductions ~70% from baseline sustained at 12 weeks at 700 mg dose
- Phase 1 healthy volunteer trial (N=32): well-tolerated up to 1,400 mg, no serious adverse events, no discontinuations, no hypogammaglobulinemia
- IgA-lowering potency ~379-fold higher than sibeprenlimab, ~26-fold higher than povetacicept (cross-study comparison)
- Half-life at steady state ~24.2 days, ~8.7-fold longer than povetacicept, ~2.6-fold longer than sibeprenlimab
- Phase 2 IgAN trial (JUNIPER) initiated, interim data expected 2027
- Registrational Phase 3 trial planned for first half of 2027
- Cash of $311 million as of March 31, 2026; runway into 1H 2028
- Company estimates IgAN as $20B+ potential U.S. market alone
Financial Impact
No revenue or financial guidance provided; $311M cash position supports development into 1H 2028
Risk Factors
- Interim Phase 1 data in healthy volunteers may not fully translate to IgAN patients
- Cross-study comparisons to competitors are not head-to-head and may overstate differentiation
- Phase 2/3 clinical or regulatory delays could push timelines
- IgAN is a competitive landscape with multiple anti-APRIL/BAFF agents in development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-249763 |
| Document: d124589dex991.htm | 0001193125-26-249763 |
| Document: 0001193125-26-249763-index-headers.html | 0001193125-26-249763 |
| Document: 0001193125-26-249763-index.html | 0001193125-26-249763 |
| Document: 0001193125-26-249763.txt | 0001193125-26-249763 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 27d ago | 8-K | $14.05 $13.77 | ▼ −1.99% | ▼ −3.91% | $14.81 (+5.41%) |
Aug 10, 2026 11w ago | 8-K | $21.73 $23.45 | ▲ +7.92% | ▲ +7.96% | $14.81 (−31.85%) |
Aug 10, 2026 11w ago | Press Release | $21.73 $23.45 | ▲ +7.92% | ▲ +7.96% | $14.81 (−31.85%) |
Jun 5, 2026 20w ago | Press Release | $14.98 $16.10 | ▼ −7.48% | ▼ −5.37% | $14.81 (+1.13%) |
Jun 4, 2026 20w ago | 8-K | $16.94 $15.34 | ▲ +9.45% | ▲ +10.01% | $14.81 (+12.57%) |
Jun 4, 2026 20w ago | 424B5 | $16.94 $15.34 | ▲ +9.45% | ▲ +10.01% | $14.81 (+12.57%) |
Jun 3, 2026 20w ago | Press Release | $17.74 $16.08 | ▲ +9.36% | ▲ +6.80% | $14.81 (+16.52%) |
Jun 3, 2026 20w ago | 424B5 | $17.74 $16.08 | ▲ +9.36% | ▲ +6.80% | $14.81 (+16.52%) |
Jun 3, 2026 20w ago | Press Release | $17.74 $16.08 | ▲ +9.36% | ▲ +6.80% | $14.81 (+16.52%) |
Jun 1, 2026 21w ago | 8-K | $18.59 $16.94 | ▼ −8.88% | ▼ −6.13% | $14.81 (−20.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers